Novo Nordisk A/S (NYSE:NVO) Releases Earnings Results, Beats Estimates By $0.03 EPS

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Wednesday. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03, Zacks reports. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $0.54 during midday trading on Friday, reaching $87.71. The company’s stock had a trading volume of 1,072,059 shares, compared to its average volume of 9,235,082. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The business’s fifty day simple moving average is $91.86 and its 200-day simple moving average is $111.83. The company has a market capitalization of $393.62 billion, a P/E ratio of 28.44, a P/E/G ratio of 0.93 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 23.30%.

Wall Street Analysts Forecast Growth

Several analysts have commented on NVO shares. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.